-
WuXi Biologics and Candid Therapeutics Ink Global Research Agreement for Trispecific T-cell Engager
•
China-based Contract Research, Development and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced a research service cooperation agreement with US-headquartered Candid Therapeutics, Inc. This strategic partnership aims to accelerate the development of innovative T-cell engagers for autoimmune and inflammatory diseases. Terms of the AgreementUnder the terms of the agreement,…
-
Candid Therapeutics Expands TCE Portfolio with Strategic Partnerships in Autoimmune Disease Treatment
•
US-based Candid Therapeutics Inc. is fulfilling its ambition to become a leader in advancing T-cell engagers (TCEs) for B-cell depletion to treat autoimmune diseases, with the signing of Chinese firms Nona Biosciences and EpimAb Biotherapeutics, Inc., as well as compatriot firm Ab Studio, Inc., in a single day to strengthen…
-
Harbour BioMed Licenses HBM7008 to Cullinan Oncology for US Development
•
Harbour BioMed (HBM), which operates out of the Netherlands, the United States, and Suzhou, China, has announced a licensing agreement with US firm Cullinan Oncology, Inc. The deal grants Cullinan exclusive rights to develop and commercialize HBM7008 in the United States (including the District of Columbia and Puerto Rico). This…
